Treatments for recurrent penile cancer

Recurrent penile cancer means that the cancer has come back after it has been treated. The following are treatment options for recurrent penile cancer. The treatment for recurrent cancer depends on where the cancer comes back and what treatments were used before. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.

Surgery

You may be offered surgery for recurrent penile cancer. The types of surgery used are:

Partial or total penectomy is surgery that removes part or all of the penis.

Lymph node dissection may be used to remove lymph nodes that have cancer.

Radiation therapy

You may be offered external beam radiation therapy or brachytherapy for recurrent penile cancer. Radiation therapy may be given:

  • instead of surgery
  • before surgery (neoadjuvant radiation therapy)
  • after surgery (adjuvant radiation therapy)

Drug therapy

You may be offered chemotherapy for recurrent penile cancer. Chemotherapy may be given:

  • before surgery
  • after surgery
  • along with radiation therapy (called chemoradiation)

Clinical trials

Some clinical trials in Canada are open to men with penile cancer. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.

Expert review and references

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2024 Canadian Cancer Society